PHS 398/2590 (Rev. 11/07) Page Biographical Sketch Format Page Curriculum Vitae James Tahara Handa, MD DEMOGRAPHIC INFORMATION Current Appointment: Robert Bond Welch, MD Professor Wilmer Eye Institute, Department of Ophthalmology Johns Hopkins University School of Medicine Baltimore, MD 07/01-present Mailing Address: 400 N. Broadway Smith Building, Room 3015 Baltimore, MD 21287-9277 (410) 614-4211 (Office) (410) 614-5471 (Fax) [email protected]Education and Training (in chronological order): Degrees/Year/Institution/Discipline Undergraduate: Degree: A.B. 1981 Brown University, Providence, RI Discipline: Biology Doctorate: Degree: M.D. 1986 University of Pennsylvania School of Medicine, Philadelphia, PA Discipline: Medicine Internship: 1986-87 The Graduate Hospital, Philadelphia, PA Discipline: Internal medicine Residency: 1987-90 The Wills Eye Hospital, Philadelphia, PA Discipline: Ophthalmology Fellowship: 1990-92 Duke University Eye Center, Durham, NC Discipline: Vitreoretinal diseases 1993 University of Southern California Children's Hospital of Los Angeles, Los Angeles, CA Discipline: Intraocular Oncology
Transcript
PHS 398/2590 (Rev. 11/07) Page Biographical Sketch Format Page
Curriculum Vitae James Tahara Handa, MD
DEMOGRAPHIC INFORMATION Current Appointment:
Robert Bond Welch, MD Professor Wilmer Eye Institute, Department of Ophthalmology Johns Hopkins University School of Medicine Baltimore, MD 07/01-present Mailing Address: 400 N. Broadway Smith Building, Room 3015 Baltimore, MD 21287-9277
Education and Training (in chronological order): Degrees/Year/Institution/Discipline Undergraduate: Degree: A.B. 1981 Brown University, Providence, RI Discipline: Biology Doctorate: Degree: M.D. 1986
University of Pennsylvania School of Medicine, Philadelphia, PA Discipline: Medicine Internship: 1986-87 The Graduate Hospital, Philadelphia, PA Discipline: Internal medicine Residency: 1987-90 The Wills Eye Hospital, Philadelphia, PA Discipline: Ophthalmology Fellowship: 1990-92 Duke University Eye Center, Durham, NC Discipline: Vitreoretinal diseases 1993 University of Southern California Children's Hospital of Los Angeles, Los Angeles, CA Discipline: Intraocular Oncology
2
Professional Experience (in chronological order): Positions/Institutions/Dates 8/81–8/82 Chemistry Instructor as the Mailliard Teaching Fellow The Taft School, Watertown, CT 7/92-6/93 Clinical Instructor and Research Associate, Vitreoretinal Service Duke University Eye Center, Durham, NC 7/93-6/99 Assistant Professor in Residence of Ophthalmology Vitreoretinal and Ocular Oncology Service University of California, Davis Medical Center University of California, Davis, Sacramento, CA 7/99-6/01 Associate Professor in Residence of Ophthalmology, Level I Vitreoretinal and Ocular Oncology Service University of California, Davis Medical Center 7/01-present Associate Professor Retina Division, Wilmer Eye Institute Johns Hopkins School of Medicine Baltimore, MD 06/08-present Professor Retina Division, Wilmer Eye Institute Johns Hopkins School of Medicine Baltimore, MD RESEARCH ACTIVITIES Publications Peer-reviewed scientific articles 1. Handa JT, Henry J, Krupin T, Keates E: Extracapsular Cataract Extraction With Posterior Chamber
Lens Implantation in Patients with Glaucoma. Arch. Ophthalmol 1987; 105: 765-769. 2. Potter W, Nelson L, Handa JT: Hemihang-Back Recession. Description of the Technique and Review
of the Literature. Ophthalmic Surg. 1990; 21: 711-715. 3. Berkowitz BA, Handa JT, Wilson CA: Perfluorocarbon temperature measurements using 19F NMR.
NMR in Biomed. 1992; 5: 65-68. 4. Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa JT, de Juan E: Treatment with intravitreal steroid
reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol. 1992; 110: 1155-1159.
5. Handa JT, Murad S, Jaffe GJ: Minoxidil inhibits ocular cell growth and lysyl hydroxylase activity. Invest Ophthalmol Vis Sci. 1993; 34: 567-575.
6. Handa JT, Houston LL, Jaffe GJ: Monensin enhances the antiproliferative effect of immunotoxin in vitro. Current Eye Res. 1993; 12: 45-53.
7. Handa JT, Houston LL, Jaffe GJ: The antiproliferative effect of a transferrin toxin on human RPE cells and rabbit fibroblasts. Invest Ophthalmol Vis Sci. 1993; 34: 3419-3428.
8. Handa JT, Murad S, Jaffe GJ: Hydroxy derivatives of minoxidil inhibit the proliferation and lysyl hydroxylase activity of cultured human RPE cells. Invest Ophthalmol Vis Sci. 1994; 35:463-469.Handa JT, Jaffe GJ: Lightning maculopathy. A case report. Retina. 1994; 14: 169-172.
10. Handa JT. The role of vitrectomy in rhegmatogenous retinal detachment. Seminars of Ophthalmology. 1995; 10: 9-16.
11. Handa JT, Berkowitz BA, Wilson CA, Ando N, Sen H, Jaffe GJ: Hypoxia precedes the development of experimental preretinal neovascularization. Graefes Arch Clin Exp Ophthalmol; 1996; 234: 43-46.
3
12. Handa JT, Keithahn MA, Jaffe GJ: Transferrin-Ricin A chain toxin prevents the development of experimental proliferative vitreoretinopathy. Exp Eye Res. 1996; 62: 689-696.
13. Handa JT, Pearson PA, Jaffe GJ: Clearance of antitransferrin receptor immunotoxin from the rabbit eye. Curr Eye Res. 1996; 15: 1039-1044.
14. Vander JF, Handa J, McNamara JA, Trese MT, Spencer R, Repka MX, Rubsamen P, Li H, Morse LS, Tasman WS: Early Treatment of Posterior Retinopathy of Prematurity: A Controlled Trial. Ophthalmology. 1997; 104: 1731-1736.
15. Handa JT, Reiser KM, Matsunaga H, Hjelmeland LM: The advanced glycation endproduct pentosidine induces the expression of PDGF-B in human retinal pigment epithelial cells. Exp Cell Res. 1998; 66: 411-419
16. Chang A, Morse LS, Handa JT, Morales RB, Tucker R, Hjelmeland L, Yannuzzi LA: Histologic localization of Indocyanine Green dye in aging primate and human ocular tissues with clinical angiographic correlation. Ophthalmology. 1998; 105: 1060-1068.
17. Matsunaga H, Handa JT, Aotaki-Keen A, Sherwood SW, West MD, Hjelmeland LM: ß-Galactosidase histochemistry and telomere loss in senescent retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1999; 40: 197-202.
18. Handa JT, Verzijl N, Matsunaga H, Aotaki-Keen A, Lutty GA, te Koppele JM, Miyata T, Hjelmeland LM:
Increase of the advanced glycation endproduct pentosidine in Bruch’s membranes with age. Invest Ophthalmol Vis Sci. 1999; 40: 775-779.
19. Mishima K, Handa JT, Aotaki-Keen A, Lutty GA, Morse LS, Hjelmeland LM: Senescence Associated ß-Galactosidase Histochemistry for the Primate Posterior Pole. Invest Ophthalmol Vis Sci. 1999; 40: 1590-1593.
20. Farboud B, Aotaki-Keen A, Miyata T, Hjelmeland LM, Handa JT. Development of a Polyclonal Antibody with Broad Epitope Specificity for Advanced Glycation Endproducts and Its Use for the Detection of AGEs in Aging Human Bruch's Membrane and Choroid. Mol Vis. 1999; 5:11: http://www.molvis.org/molvis/v5/p11/
21. Canzano JC, Handa JT. Utility of Pupillary Dilation for Detecting Leukocoria in Patients with Retinoblastoma. Pediatrics. 1999; 104(4): e44.
22. Matsunaga H, Handa JT, Gelfman CM, Hjelmeland LM: The mRNA Phenotype of Human RPE Cells at Replicative Senescence. Mol Vis. 1999; 5: 39. http://www.molvis.org/molvis/v5/p39/
23. Hong S-B, Kwang-Won L, Handa JT, Joo C-K. Effect of advanced glycation end products on lens epithelial cells in vitro. Biophys Biochem Res Commun. 2000; 275: 53-59.
24. Honda, S, Hjelmeland, LM, Handa JT. The use of hyperoxia to induce chronic mild oxidative stress in RPE cells in vitro. Mol Vis. 2001; 7: 63-70 http://www.molvis.org/molvis/v7/a10/.
25. Miyamura N, Mishima K, Honda S, Aotaki-Keen AE, Morse LS, Handa JT, Hjelmeland LM. Age-related and Topographic variation of insulin-like growth factor binding protein 2 expression in the human RPE. Invest Ophthalmol Vis Sci. 2001; 42: 1626-1630.
26. Honda S, Weigel A, Hjelmeland LM, Handa JT. Senescence of retinal pigment epithelial cells induced by cryopreservation accompanied with telomere shortening. Biophys Biochem Res Commun. 2001; 282: 493-498.
27. Honda S, Hjelmeland LM, Handa JT. Oxidative stress induced single strand breaks in chromosomal telomeres of human retinal pigment epithelial cells in vitro. Invest Ophthalmol Vis Sci. 2001; 42: 2139-2144.
28. Boylan S, Honda S, Hjelmeland LM Handa JT. An optimized protocol for first strand cDNA synthesis from laser capture microdissected tissue. Lab Invest. 2001; 81: 1167-1169.
29. Alizadeh M, Wada M, Gelfman CM, Handa JT, Hjelmeland LM. Downregulation of differentiation specific gene expression by oxidative stress in ARPE-19 cells. Invest Ophthalmol Vis Sci. 2001; 42: 2706-2713.
30. Wada M, Gelfman CM, Honda S, Matsunaga H, Alizadeh M, Morse LS, Handa JT, Hjelmeland LM. Density dependent expression of FGF-2 in response to oxidative stress in RPE cells in vitro. Curr Eye Res. 2001; 23: 226-231.
31. Honda S, Farboud B, Hjelmeland LM, Handa JT. Induction of an aging mRNA retinal pigment epithelial cell phenotype by matrix-containing advanced glycation endproducts in vitro. Invest Ophthalmol Vis Sci. 2001; 42: 2419-2425.
32. Rasmussen H, Chu KW, Campochiaro P, Gehlbach PL, Haller JA, Handa JT, Nguyen QD, Sung JU. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of
4
ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Human Gene Ther. 2001; 12: 2029-2032.
33. Honda S, Hjelmeland LM, Handa JT. Senescence-associated beta-galactosidase activity in human retinal pigment epithelial cells exposed to mild hyperoxia in vitro. Br J Ophthalmol. 2002; 86: 159-162.
35. Chen L, Miyamura N, Ninomiya Y, Handa JT. Distribution of the Collagen IV isoforms in human Bruch’s Membrane. Br J Ophthalmol. 2003; 87: 212-215.
36. Alizadeh M, Miyamura N, Handa JT, Hjelmeland LM. Human RPE cells express the FGFR2IIIc and FGFR3IIIc splice variants and FGF9 as a potential high affinity ligand. Exp Eye Res. 2003; 76: 249-256.
37. Miyamura N, Ogawa T, Boylan S, Morse LS, Handa JT, Hjelmeland LM. Topographic and age-dependent expression of heme-1 and catalase in the human retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2004; 45:1562-1565.
38. Tian J, Ishibashi K, Handa JT. The expression of native and cultured RPE grown on different matrices. Physiologic Genomics. 2004;17: 170-182.
39. Ida H, Ishibashi K, Reiser KM, Hjelmeland LM, Handa JT. Ultrastructural Aging of the RPE-Bruch’s Membrane-Choriocapillaris Complex in the D-Galactose Treated Mouse. Invest Ophthalmol Vis Sci. 2004; 45(7):2348-54..
40. Honda S, Hirai T, Handa JT, Okuno T, Saito I. The expression of cell cycle related proteins in a rapidly growing uveal malignant melanoma. Retina, 2004; 24(4): 646-9.
41. Ishibashi K, Tian J, Handa JT. Similarity of mRNA Phenotypes of Morphologically Normal Macular and Peripheral Retinal Pigment Epithelial Cells in Older Human Eyes. Invest Ophthalmol. Vis Sci. 2004; 45(9): 3291-301.
42. Apte RJ, Schachat AP, Dibernardo C, Handa JT. Retinal Vascular Occlusion with Overlying Vitreous Hemorrhage Masquerading as a Tumor. Arch Ophthalmol. 2005; 123(2):272-4.
43. Apte RJ, Al-Abdulla NA, Green WR, Schachat AP, DeJong MR, Dibernardo C, Handa JT. Systemic Non-hodgkin B-Cell Lymphoma Presenting as a Vanishing Choroidal Mass. Arch Ophthalmol. 2005; 123(1):105-9.
44. Wu T, Handa JT, Gottsch JD. Light Induced-oxidative Stress in Choroidal Endothelial Cells. Invest Ophthalmol. Vis Sci. 2005; 46(4):1117-23.
45. Lai MM, Lai JC, Lee W-H, Huang JJ, Patel S, Ying HS, Melia M, Haller JA, Handa JT. Comparison of Retrobulbar and Sub-Tenon’s Injection of Local Anesthetic in Vitreoretinal Surgery. Ophthalmology. 2005; 112(4):574-9.
46. Oshima Y, Oshima S, Nambu H, Kachi S, Takahashi K, Umeda N, Shen J, Dong A, Apte RS, Duh E, Hackett SF, Okoye G, Ishibashi K, Handa J, Melia M, Wiegand S, Yancopoulos G, Zack DJ, Campochiaro PA. Different effects of angiopoietin-2 in different vascular beds in the eye: new vessels are most sensitive. FASEB J. 2005 Jun;19(8):963-5. Epub 2005 Mar 31.
47. Leung L, Handa JT. Treatment of primary rhegmatogenous retinal detachment. Clinical Update. American Academy of Ophthalmology. 2005.www.aao.org/vp/edu/retina/v1m3
48. Tian J, Ishibashi K, Honda S, Boylan SA, Hjelmeland LM, Handa JT. The Expression of Native and Cultured Human Retinal Pigment Epithelial Cells Grown in Different Culture Conditions. Br J Ophthalmol. 2005; 89(11):1510-7.
49. Barak A, Hauser D, Yipp P, Morse L, Leigh B, Kubo D, Goldberg Z, Earle J, Handa JT. A Phase I trial of stereotactic external beam radiation for subfoveal choroidal neovascular membranes in age-related macular degeneration. Br J. Radiol. 2005; 78(933):827-31.
50. Tian J, Ishibashi K, Ishibashi K, Reiser K, Grebe R, Biswal S, Gehlbach P, Handa JT. Advanced Glycation Endproduct-Induced Aging of the Retinal Pigment Epithelium and Choroid: A Comprehensive Transcriptional Response . Proc Natl Acad Sci USA. 2005; 102(33):11846-51.
51. Lai MM, Handa JT, Local anesthetic in vitreoretinal surgery: author reply. Ophthalmology. 2005; 112(11):2052.
52. Yamada Y, Ishibashi K, Ishibashi K, Bhutto IA, Tian J, Lutty GA, Handa JT. The Expression of Advanced Glycation Endproduct Receptors in RPE Cells Associated with Basal Deposits in Human Maculas. Exp Eye Res. 2006; 82(5):840-8.
53. Leung L, Hyland JC, Young A, Goldberg MF, Handa JT. A Novel Mutation in Intron 11 of the COL2A1 Gene in a Patient with Type I Stickler Syndrome. Retina. 2006; 26(1): 106-9.
55. Do DV, Cho M, Nguyen QD, Shah SM, Handa JT, Campochiaro PA, Zimmer-Galler I, Sung JU, Haller JA. The Impact Of Optical Coherence Tomography On Surgical Decision Making In Epiretinal Membrane And Vitreomacular Traction. Trans Am Ophthalmol Soc. 2006 Dec;104:161-166.
56. Handa JT. New Molecular Histopathologic Insights Into the Pathogenesis of Age-related Macular Degeneration. Int Ophthalmol Clin. 2007 Winter;47(1):15-50.
57. Wang Z, Handa JT, Green WR, Stark WJ, Weinberg RS, Jun AS. Advanced Glycation End Products and Receptors in Fuchs' Dystrophy Corneas Undergoing Descemet's Stripping with Endothelial Keratoplasty. Ophthalmology. 2007 Aug;114(8):1453-60. Epub 2007 Feb 22.
58. Do DV, Cho M, Nguyen QD, Shah SM, Handa JT, Campochiaro PA, Zimmer-Galler I, Sung JU, Haller JA. Impact of optical coherence tomography on surgical decision making for epiretinal membranes and vitreomacular traction. Retina. 2007 Jun;27(5):552-6.
60. Sodhi, A, Leung L-S, Do DV, Gower EW, Schein OD, Handa JT. Recent Trends in the Management of Rhegmatogenous Retinal Detachment. Survey Ophthalmol. 2008, Jan-Feb;53(1):50-67.
61. Yamada Y, Tian J, Yang Y, Cutler RG, Wu T, Telljohann RS, Mattson MP, Handa JT. Oxidized low density lipoproteins induce a pathologic response by retinal pigmented epithelial cells. J Neurochem. 2008; 105(4):1187-97.
62. Khurana R, Dibernardo C, Handa JT. Improved Systemic Chemotherapy for Metastatic Testicular Choriocarcinoma can result in Excellent Prognosis for Life and Vision. Archives of Ophthalmology. 2008;126(7):1008-9.
63. Fujihara M, Nagai N, Sussan TE, Biswal S, Handa JT. Chronic Cigarette Smoke Causes Oxidative Damage and Apoptosis to Retinal Pigmented Epithelial Cells in Mice. PLoS ONE. 2008; 3: e3119.
64. Nagai N, Klimava A, Lee WH, Izumi-Nagai K, Handa JT. CTGF is increased in Basal Deposits and Regulates Matrix Production through the ERK (p42/p44mapk) MAPK and the p38 mapk signaling pathways. Invest Ophthalmol Vis Sci. 2008. 50:1903-10.
65. Fleming I, Balicki M, Koo J, Iordachita I, Mitchell B, Handa J, Hager G, Taylor R. Cooperative robot assistant for retinal microsurgery. Med Image Comput Comput Assist Interv. 2008; 11(Pt 2): 543-550.
66. Handa JT, Sodhi A. Author’s Response. Surv Ophthalmol. 2009;54:162-3. 67. Leath JD, Eller AW, Freund KB, Handa JT. Diagnostic and Therapeutic Challenges. Retina. 2009
epub. 68. Balicki M, Han JH, Iordachita I, Gehlbach P, Handa J, Taylor R, Kang J. Single fiber optical coherence
tomography microsurgical instruments for computer and robot-assisted retinal surgery. Med Image Comput Comput Assist Interv. 2009; 12(Pt 1): 108-115.
69. Wang, AL, Lukas TJ, Yuan M, Du N, Handa JT, Neufeld AH. Changes in retinal pigment epithelium related to cigarette smoke: Possible relevance to smoking as a risk factor for age-related macular degeneration. PLoS ONE. 2009; 4: e5304.
70. Nagai N, Thimmulappa RK, Cano M, Fujihara M, Izumi-Nagai K, Kong X, Sporn MB, Kensler TW, Biswal S, Handa JT. Nrf2 is a Critical Modulator of the Innate Immune Response in a Model of Uveitis. Free Radical Biol Med. 2009; 47(3):300-6.
71. Fujihara M, Bartels E, Nielsen LB, Handa JT. A human apoB100 transgenic mouse expresses human apoB100 in the RPE and develops features of early AMD. Exp Eye Res. 2009; 88: 1115-23.
72. Baranano DE, Kim SJ, Edelhauser HF, Durairaj C, Kompella UB, Handa JT. Efficacy and Pharmacokinetics of Intravitreal Nonsteroidal Anti-Inflammatory Drugs for Intraocular Inflammation. British J Ophthalmol. 2009; Oct;93(10):1387-90
73. Iordachita I, Sun Z, Balicki M, Kang JU, Phee SJ, Handa J, Gehlbach P, Taylor R. A sub-millimetric, 0.25 mN resolution fully integrated fiber-optic force-sensing tool for retinal microsurgery. Int J Comput Assist Radiol Surg. 2009; 4(4): 383-390. Epub 2009 Apr 15.
74. Ayres MB, Handa JT, Iliff N, Green WR, DiBernardo C. Foreign Body Granuloma Masquerading as Extrascleral Extension Following Brachytherapy For Choroidal Melanoma. Retinal Cases and Brief Reports. 3 (4); 326-328, Fall 2009.
75. A.) Wu T, Tian J, Cutler RG, Telljohann RS, Bernlohr DA, Mattson MP, Handa JT. Knockdown of FABP5 mRNA decreases cellular cholesterol levels and results in decreased apoB100 secretion and triglyceride accumulation in ARPE-19 cells. Lab Invest. 2009 epub; 2010; 90(6): 906-14. B.) Wu T,
6
Tian J, Cutler RG, Telljohann RS, Bernlohr DA, Mattson MP, Handa JT. Knockdown of FABP5 mRNA decreases cellular cholesterol levels and results in decreased apoB100 secretion and triglyceride accumulation in ARPE-19 cells. Lab Invest. 2010; 90(6):963-5. Corrigendum.
76. Cano M, Thimmalappula R, Fujihara M, Nagai N, Sporn M, Wang AL, Neufeld AH, Biswal S, Handa JT. Cigarette smoking, oxidative stress, the anti-oxidant response through Nrf2 signaling, and Age-related Macular Degeneration. Vision Res. 2010 Mar 31;50(7):652-64 Aug 22.
77. Savige J, Liu J, DeBuc DC, Handa JT, Hageman GS, Wang YY, Parkin JD, Votee B, Fassett R, Sarks S, Colville D. Retinal basement membrane abnormalities and the retinopathy of Alport syndrome. Invest Ophthalmol Vis Sci 2010; 51: 1621-1627.
78. Wu, T, Fujihara M, Tian J, Jovanovic M, Grayson C, Cano M, Gehlbach P, Margaron P, Handa JT. Apolipoprotein B100 secretion by cultured ARPE-19 cells is modulated by alteration of cholesterol levels. J Neurochem. 2010; 114; 1734-1744.
79. DiBernardo CW, Parekh P, Handa JT, Goldberg MF: The Suboptimal Role of OCT in Diagnosing Choroidal Metatasis in the Macula. Retinal Cases and Brief Reports. 4 (4);326-400, Fall 2010.
80. Balicki M, Uneri A, Iordachita I, Handa J, Gehlbach P, Taylor R: Micro-force sensing in robot assisted membrane peeling for vitreoretinal surgery. Med Image Comput Comput Assist Interv. 2010;13(Pt 3):303-10.
81. Sznitman R, Rother D, Handa J, Gehlbach P, Hager GD, Taylor R: Adaptive multispectral illumination for retinal microsurgery. Med Image Comput Comput Assist Interv. 2010;13(Pt 3):465-72.
82. Becker BC, Voros S, Lobes LA, Handa JT, Hager GD, Riviere CN. Retinal vessel cannulation with an image-guided handheld robot. Conf Proc IEEE Eng Med Biol Soc. 2010;1:5420-3.
83. Zigler JS, Zhang C, Grebe R, Sehrawat G, Hackler L, Adhya S, Hose S, McLeod DS, Bhutto I, Barbour W, Parthasarathy G, Zack DJ, Sergeev Y, Lutty GA, Handa JT, Sinha D. Mutation in the βA3/A1-crystallin gene impairs phagosomes degradation in the retinal pigmented epithelium of the rat. J Cell Sci. 2011; Jan 25 epub.
84. Zhang C, Asnaghi L, Gongora C, Patek B, Hose S, Ma B, Fard MA, Brako L, Singh K, Goldberg MF, Handa JT, Lo WK, Eberhart CG, Zigler JS Jr, Sinha D. A developmental defect in astrocytes inhibits programmed regression of the hyaloids vasculature in the mammalian eye. Eur J Cell Biol. 2011. Feb 25 [Epub ahead of print].
85. Uneri A. Balicki MA, Handa J, Gehlbach P, Taylor RH, Iordachita I. New Steady-Handa Eye Robot with Micro-Force Sensing for Vitreoretinal Surgery. Proc IEEE RAS EMBS Int Conf Biomed Robot Biomechatron. 2010; Sep 1;(26-29):814-819.
86. Wei Y, Gong J, Yoshida T, Eberhart CG, Xu Z, Kombairaju P, Sporn MB, Handa JT, Duh EJ. Nrf2 has a protective role against neuronal and capillary degeneration in retinal ischemia-reperfusion injury. Free Radic Biol Med. 2011. Epub
87. Cano M, Fijalkowski N, Kondo N, Dike S, Handa JT. Advanced Glycation Endproduct Changes to Bruch’s Membrane Promotes Lipoprotein Retention by Lipoprotein Lipase. Am J Pathol. 2011. In press.
88. Chen CJ, McCoy AN, Brahmer J, Handa JT. Emerging Treatments for Choroidal Metastases. Survey Ophthalmal. 2011. In press.
89. Ebrahimi KB, Handa JT. Lipids, Lipoproteins, and Age-Related Macular Degeneration. J Lipids. 2011. In press.
JT Handa, M.D. 7
7
Peer Reviewed Bioengineering Publications (Role: Investigator) NOTE: The following meetings have a 5-30% acceptance rate due to 3 reviews of full papers before acceptance.
1. Lin H, Dewan M, Marayong P, Handa J, Hager GD. Vision-Based Human-Machine
Collaborative System for Ophthalmic Micro-Surgery. Medicine Meets Virtual Reality, 2006.
2. Seshamani S, Riviere C, Handa JT, Lobes L, Hager GD, "Visual Measurement of Microsurgical Motion with Application to Robotic Augmentation," IEEE 32nd Northeast Bioengineering. Conference Proceedings, pages 39-40, 2006
3. Iordachita I , Kapoor A, Mitchell B, Kazanzides P, Hager G, Handa J, and Taylor R. Steady-Hand Manipulator for Retinal Surgery. Miccai Medical Robotics Workshop, Copenhagen, Denmark, Oct 5, 2006.
4. Mitchell B, Koo J, Iordachita I, Kazanzides P, Kapoor A, Handa J, Taylor R, and Hager G. Development and Application of a New Steady-Hand Manipulator for Retinal Surgery, IEEE International Conference on Robotics and Automation, Rome, Italy, Apr 10-14, 2006.
5. Fleming I, Voros S, Vagvolgyi B, Pezzementi Z, Handa J, Taylor R, and Hager G. Intraoperative visualization of anatomical targets in retinal surgery. In Proc. IEEE Workshop on Applications of Computer Vision. IEEE Catalog Number: CFP08082-CDR ISBN: 978-1-4244-1914-2 ISSN: 1550-5790, January, 2008.
6. Fleming I, Balicki M, Koo J, Iordachita I, Mitchell B, Handa J, Hager G, Taylor R. Cooperative Robot Assistant for Retinal Microsurgery. MICCAI Medical Robotics Workshop, 2008; 11(Pt 2):543-50.
7. Sun Z., Balicki M., Kang J., Handa J., Taylor R., Iordachita I., "Development and Preliminary Data of Novel Integrated Optical Micro-Force Sensing Tools for Retinal Microsurgery", 2009 IEEE International Conference on Robotics and Automation - ICRA 2009, Kobe, Japan, May 2009 (Accepted)
8. Han J-H, Balicki M, Zhang K, Liu X, Handa J, Taylor R, Kang JU. Common-path Fourier-domain optical coherence tomography with a fiber optic probe integrated into a surgical needle, 2009 CLEO.
9. Sun Z., Balicki M., Kang J., Handa J., Gehlbach P, Taylor R., Iordachita I. A Sub-Millemetric, 0.25 mN Resolution Fully Integrated Fiber-Optic Force Sensing Tool for Retinal Microsurgery. International Journal of Computer Assisted Radiology and Surgery 2009; 4: 383-390.
10. Balicki M., Han J-H., Iordachita I., Kang J., Gehlbach P., Handa J., Taylor R. Single Fiber Optical Coherence Tomography Microsurgical Instruments for Computer and Robot-Assisted Retinal Surgery. MICCAI 2009 (Oral presentation). * Awarded “Best CAI Paper”.
11. Sznitman R, Basu A, Richa R, Handa J, Gehlbach P, Taylor R, Jedynak B, Hager G. Unified Detection and Tracking in Retinal Microsurgery. MICCAI 2011
Collaborative Study Publications (Role: Investigator) 1. Early Treatment For Retinopathy Of Prematurity Cooperative Group.
Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003 Dec;121(12):1684-94.
2. Hardy RJ, Palmer EA, Dobson V, Summers CG, Phelps DL, Quinn GE, Good WV, Tung B; Cryotherapy for Retinopathy of Prematurity Cooperative Group. Risk analysis of prethreshold retinopathy of prematurity. Arch Ophthalmol. 2003 Dec;121(12):1697-701.
JT Handa, M.D. 8
8
3. Campochiaro PA and the C99-PKC412-003 Study Group. Reduction of Macular Edema by Oral Administration of the Kinase Inhibitor PKC412. Invest Ophthalmol Vis Sci. 2004; 45: 937-942.
4. Good WV on behalf of the Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) Randomized Trial. Trans Am Ophthalmol Soc 2004;102:233-250
5. Early Treatment for Retinopathy of Prematurity Cooperative Group. Multicenter trial of early treatment for retinopathy of prematurity: study design. Controlled Clinical Trials 2004; 25:311–325.
6. Davitt BV, Dobson V, Good WV, Hardy RJ, Quinn, GE, Siatkowski RM, Summers CG, Tung T. for the Early Treatment for Retinopathy of Prematurity Cooperative Group. Prevalence of Myopia at 9 Months in Infants with High-Risk Prethreshold Retinopathy of Prematurity. Ophthalmology 2005;112:1564-1568.
7. Early Treatment for Retinopathy of Prematurity Cooperative Group. The Incidence and Course of Retinopathy of Prematurity: Findings From the Early Treatment for Retinopathy of Prematurity Study. Pediatrics 2005;116;15-23.
8. VanderVeen DK, Coat DK, Dobson V, Fredrick D, Gordon RA, HardyRJ, Neely DE, Palmer EA Steid SM, Tung B, Good WV, for the Early Treatment for Retinopathy of Prematurity Cooperative Group. Prevalence and Course of Strabismus in the First Year of Life for Infants With Prethreshold Retinopathy of Prematurity. Findings From the Early Treatment for Retinopathy of Prematurity Study. Arch Ophthalmol. 2006;124:766-773.
9. Early Treatment for Retinopathy of Prematurity Cooperative Group. The Early Treatment for Retinopathy Of Prematurity. Study: structural findings at age 2 years. Br. J. Ophthalmol. 2006;90;1378-1382; originally published online 16 Aug 2006; doi:10.1136/bjo.2006.098582.
10. Nguyen QD, Shah SM, Hafiz G, Quinlan E, Sung J, Chu K, Cedarbaum JM, Campochiaro PA, CLEAR-AMD 1 Study Group. A Phase I Trial of an IV-Administered Vascular Endothelial Growth Factor Trap for Treatment in Patients with Choroidal Neovascularization due to Age-Related Macular Degeneration. Ophthalmology. 2006 Jul 27; [Epub ahead of print]
11. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Singerman LJ, Tolentino M, Chan CK, Gonzalez VH; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol. 2009 Sep;127(9):1101-14.
12. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK, Gonzalez VH, Singerman LJ, Tolentino M; SCORE Study Research Group. Arch Ophthalmol. 2009 Sep;127(9):1115-28
13. Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA, Antoszyk AN; SCORE Study Investigator Group. SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe design. Am J Ophthalmol. 2009 Nov: 148(5): 725-732 e7. Epub 2009 Aug 11.
14. Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, Abraham P, Campochiaro PA; READ-2 Study Group. Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2009; 116(11): 2175-81.
15. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group.
JT Handa, M.D. 9
9
Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6):1134-1146.e3. Epub 2010 Apr 24.
16. Early Treatment for Retinopathy of Prematurity Cooperative Group, Good WV, Hardy RJ, Dobson V, Palmer EA, Phelps DL, Tung B, Redford M. Final visual acuity results in the early treatment for retinopathy of prematurity study. Arch Ophthalmol. 2010 Jun;128(6):663-71. Epub 2010 Apr 12.
Non-peer reviewed articles 1. Tzu J, Handa JT, Kuo IC. The case of the cardiac patient with cotton wool spots and visual loss. Morning Rounds. EyeNet. June 2008. Editorials, Reviews (If invited, list below under “Recognition”) Book Chapters, Monographs 1. Handa JT. Pathophysiology of the RPE and Choroid. In: Quiroz-Mercado H, Tano Y,
Meiler WF, Alfaro DV, Liggett PE, Kerrison JB (eds). Macular Surgery, 2nd Edition. Lippincott Williams & Wilkens, Baltimore (in press).
2. Handa JT. The Multiple Factors Involved in the Development of Non-Neovascular Age-related Macular Degeneration. In: Fini E (ed). Molecular and Cellular Biology of the Eye, 1st Edition. Elsevier LTD, Oxford, UK (in press).
4. Dibernardo C and Handa JT. How do I know if there is a retinal detachment or a tumor when I am doing ultrasonography? In: Fekrat S. (Chief Ed). Curbside Consultation in Retina. Slack Inc. 2010.
Books 1. 1989 Co author: In Friedberg M, Rapuano C (Eds.): Wills Eye Hospital: Office and
Emergency Room Diagnosis and Treatment of Eye Diseases, Philadelphia. J.B. Lippincott.
2. 2013 Section Editor, Translational Visual Neurosciences Section. In Chalupa and Werner (Eds.): Visual Neurosciences, 2nd Edition. Cambridge, MA. MIT Press.
Other Media-None Inventions, Patents, Copyrights (pending, awarded):
1. SNAKE 2. Surgical Instrument with integrated forward looking Optical Coherence Tomography. ROI
submitted 2009 3. Programmable Multispectral Illumination System for Surgery and Visualization of Light-
Sensitive Tissues. 2009. JHU reference #C10789. Extramural Sponsorship (current, pending, previous): Current. Bank of America Thome Foundation (PI Handa) $250,000 12/15/09-12/14/12
JT Handa, M.D. 10
10
Cigarette Smoking Induces Oxidative Damage and an Enhanced Innate Immune Response during Early Age-related Macular Degeneration. The goal of this project is to determine if smoking induces both complement and Toll-like receptor activation in a mouse model of AMD. Role: PI; % effort: 1.8 cal mo (15%) NIH 2R01 EY14005-06 9/1/08-8/31/12 “AGE-induced Phenotype of the Retinal Pigment Epithelium." The goal of this project is to determine how lipoproteins cause basal deposit formation in early Age-related macular degeneration. Role: PI Direct Cost, current year: $322,517; Total Direct: $1,675,191 % Effort: 4.8 cal mo (40%) NIH R01 1 R01 EY019904-01 2/1/10-1/31/13 Nrf2 signaling and oxidative stress in Age-related macular degeneration The goal of this project is to determine whether Nrf2 signaling influences oxidative stress and AMD. Role: PI % Effort: 3.6 cal mo (30%) Total Direct: 1,945,438 NIH BRP R01 EB007969-01 (PI Taylor) 8/1/08-7/30/13 “Microsurgical Assistant system” The goal of this project is to develop a computer, robotic assisted surgical system for Vitreoretinal surgery. Role: Investigator, Clinical Director Direct Cost, current year: $749,601; Total direct: $3,747,322 % Effort: 1.2 calendar months (10%) Beckman Foundation Grant 10/1/11-9/30/12 Does Lp(a) protect the fundus from oxidized phospholipids? The goal of this study is to determine if Lp(a) binds oxidized phospholipids in the retina Role: PI % Effort: 0.6 cal mo (5%) Total Direct: $100,000 . Pending International Retina Research Foundation. 9/1/2011-8/31/2012 “Does Complement Factor H scavenge Oxidation Specific Epitopes in the Fundus?” The goal of this study is to determine if CFH binds to MDA as a protective function against development of AMD. Role: PI % Effort: 0.6 cal mo (5%) Total Direct: $100,000 Research to Prevent Blindness 12/1/2011-11/30/2012 Senior Scientist Award “Pattern Recognition Receptors in AMD” The goal of this study is to identify all of the relevant PRRs that are found in maculas of AMD patients.
JT Handa, M.D. 11
11
Role: PI % Effort: 0.6 cal mo (5%). Total Direct: $75,000. Previous NIH/ R01 EY 04859 (PI D. Zack) 7/1/06-6/30/11 Visual Neurons--Development and Regeneration In Vitro The long term goal is to investigate the extracellular signaling molecules and intracellular regulatory mechanisms controlling retinal cell differentiation in general and photoreceptor differentiation in particular. Role: Investigator Current year:$ 393,889; Total direct: $1,597,121 % Effort: 1.8 calendar months (15%) VLH Foundation. Handa (PI) 9/1/08-8/31/11 “Use of a novel genetic animal model to study the molecular pathogenesis of retinal hemangioblastomas in von Hippel Lindau (VHL) disease” The goal of this project is to determine the mechanism of retinal hemangioblastomas development. Role: PI Current year: $40,000; Total direct: $120,000 % Effort: 0.36 calendar months (3%, but 0% salary) QLT Award. Handa (PI) 12/19/06-12/18/08 QLT, Inc. . Investigation of HMG-CoA Reductase Inhibitors (statins) for the Treatment of Dry AMD The goal of this project is to determine whether local administration of statins reduces the AMD phenotype in mouse models. Role: PI Direct Cost, current year: $395,488; Total Direct: $889,383 % Effort: 0.24 cal mo (2%) Macula Society Award 7/1/07-6/30/08 “Role of Non-steroidal anti-inflammatory agents in reducing experimental uveitis” The goal of this work was to determine whether NSAIDS reduce inflammation in experimental uveitis. PI: Percent effort 1% effort (0% salary) Direct cost: $10,000. NIH. R21 EY016359. (PI Riviere) 8/1/06-7/30/08 "Image Guidance for Active Handheld Microsurgical Tools". Investigator, 5% effort Direct Costs: $275,000 Lincy Foundation 7/1/06-6/30/08 “Does Lipofuscin Induce Lipoprotein Secretion by the RPE?” The goal was to determine whether Lipofuscin alters apoB secretion in RPE cells. PI, 5% effort (0% salary). Direct costs: $80,000. Current year: $40,000. The Pfizer Atorvastatin Research Award (PI Gehlbach) 7/1/05-6/30/07
JT Handa, M.D. 12
12
“Uncovering a Novel Indication for Atorvastatin: Delaying the Progression of Age-related Macular Degeneration”
The goal was to determine whether Atorvastatin reduced apoB secretion in RPE cells. Investigator, 5% effort (0% salary) Direct costs: $100,000 American Health Assistance Foundation:Macular Degeneration Research 4/1/05-3/31/07 “Advanced Glycation Endproduct mediated cholesterol deposition in Bruch’s membrane of
ApoB100+/+LDLR-/- Mice” The goal was to determine whether the combination of AGEs and increased lipoprotein
deposition induced an AMD phenotype. PI, 10% effort (0% salary) Direct costs: $99,545 Research to Prevent Blindness 1/1/05-12/31/06 Physician-Scientist Award “AGEs in Basal Deposit formation”. The goal was to determine whether AGEs induce basal deposits in mice. PI, 10% effort . Direct costs: $55,000 Research to Prevent Blindness. 7/1/02-6/30/03 Lew Wasserman Award “AGE-induced aging of Bruch’s membrane” The goal was to determine the effect of AGEs on basal deposit formation. PI, 10% effort Direct costs: $55,000 National Eye Institute P30 EY 12576 1999-2004 Vision Research Core Grant (Principal Investigator: Leo Chalupa, Ph.D) Core investigator, 5% effort Total Direct costs: $1,272,254 Research to Prevent Blindness 1998-1999 Manpower Award “The role of AGEs on RPE senescence” The goal was to determine the role of AGEs on RPE senescence. PI, 10% effort Direct costs: $20,000 UC Davis Health System Research Award 1998-2000 “Induction of Senescence in RPE cells by AGEs” The goal was to determine if AGEs induce RPE cells into senescence. PI, 10% effort Direct costs: $116,138 Children’s Miracle Network Research Grant, Sacramento, CA. 1998-1999 “The Role of Anemia of Prematurity and Fetal Hemoglobin on Retinopathy of Prematurity” The goal was to determine if fetal hemoglobin influenced ROP. PI, 5% effort Direct costs: $15,000.
JT Handa, M.D. 13
13
National Eye Institute. K11 Physician Scientist Award. EY00344 1995-2001 “The effect of nonenzymatic glycation on RPE cell polarity". The goal was to determine the role of AGEs on RPE morphology. PI, 75% effort Direct costs: $413,100 Bob Hope Fight For Sight Grant-in-Aid. 1994-1995 “The role of nonenzymatic glycation in age-related macular degeneration" The goal was to determine the role of AGEs in AMD. PI, 10% effort Direct costs: $10,475 Clinical Trials Investigator for Trials on Age-related Macular Degeneration 1. An Open Label, Phase I single administration, dose escalation study of Ad PEDF.11D in
Neovascular Age-related Macular Degeneration. GenVec, Inc. 2. Combretastatin. An open label pilot (phase I/II) dose escalation safety and tolerability
study of Combretastatin A4 Phosphate in patients with Neovascular Age-related Macular Degeneration. FFB/OxiGene
3. A phase III multicenter, randomized double-masked sham injection-controlled study of the efficacy and safety of rhuFab V2 (Ranibizumab) in subjects with minimally classic or occult subfoveal neovascular age related macular degeneration. Genentech, Inc.
4. Phase I open label pilot dose escalation safety study of siRNA (VEGFR2) intravitreal injection in patients with Neovascular Age-related Macular Degeneration. Sirna, Inc.
5. VEGF-T. Phase I trial of intravenous VEGF-trap for Neovascular Age-related Macular Degeneration. Regeneron, Inc.
6. Supplemental Oxygen. A phase I/II trial of supplemental oxygen for Neovascular Age-related Macular Degeneration.
7. AREDS II. Phase III Prospective, randomized clinical trial evaluating AREDS vitamin versus AREDS with xeozanthine and omega III fatty acids.
8. VEGF Trap 0605 Intravitreal injection of VEGF Trap Phase III Regeneron, Inc 9. Fluocinolone acetonide intravitreal inserts Phase II Alimera Sciences, Inc. 10. DENALI Novartis, I 11. AREDS II Testing Lutein/ Zeathanthine/ Fish Oil Phase III National Eye Institute 12. The Genetics of Macular Degeneration Finding the genetic mutations that may
contribute to the causes of macular degeneration. Foundation Fighting Blindness Investigator for Trials on Vein Occlusions 1. SCORE (standard care vs Triamcinolone Acetonide intravitreal injections). Treatment for
CRVO, BRVO, or Hemi-RVO. NEI 2. Oculex III. Steroid treatment ofg CRVO and BRVO. 3. Ranibizumab for Central Retinal Vein Occlusion CRVO (CRUISE) Phase III Genentech 4. Ranibizumab for Branch Retinal Vein Occlusion BRVO (BRAVO) Phase III Genentech Investigator for Trials on Diabetic Macular Edema, and Diabetic Retinopathy 1. Celebrex/Laser Tx for DME. 2. Supplemental oxygen for DME 3. VEGF-T for DME. Regeneron, Inc. 4. DRCR, Intravitreal steroid study to treat DME. NEI 5. Avastin (Monoclonal anti-VEGF) to treat DME. Lucentis, Inc. 6. Oculex III. Phase III trial to treat DME.
JT Handa, M.D. 14
14
7. Fluocinolone acetonide intravitreal inserts and PK Study Subjects with DME Phase II Alimera Sciences, Inc.
8. Mecamylamine Topical Solution Subjects with DME Phase II Comentis, Inc. 9. Posurdex™ for DME Dexamethasone Posterior Segment Drug Deliver System Phase III
Allergan, Inc. 10. Ranibizumab for DME (RISE) Study Phase III Genentech, Inc. 11. DRCR Evaluation of Vitrectomy for DME National Eye Institute 12. DRCR Intravitreal Ranibizumab or Triamcinolone Acetonide in Combination with Laser
Photocoagulation for DME Phase III National Eye Institute 13. Ruboxistaurin DME Study Effect of Ruboxistaurin on CSME in patients with diabetes Eli
Lilly and Company 14. Retinal Thickness of Subjects with Diabetes Evaluation of the Retina of Subjects without
Diabetes Mellitus and Subjects with Diabetes without DR using OCT Johns Hopkins Investigator for Other Clinical Trials 1. Second Sight Medical Products: Argus™ II Retinal Stimulation System Feasibility
Protocol (for Retinitis Pigmentosa). 2. LUMINATE Studies LX211 for active panuveitis and anterior uveitis, as well as
quiescent uveitis Phase III LUX Biosciences, Inc. 3. MAC TEL A Natural History and Observational Study of Macular Telangiectasia MacTel
Foundation 4. Angiogenic AC Paracentesis Study A study to investigate the intraocular level of VEGF
and other factors in patients with diseases that are mediated by angiogenesis Johns Hopkins
5. High-Resolution Ultrasonography Study of Patients Who Have Undergone Multiple Intravitreal Injections Johns Hopkins
Instructor of Record. Cellular and Molecular Biology of Photoreceptors in Health and Disease. Department of
Neuroscience and Ophthalmology Course. Johns Hopkins School of Medicine. 2006 Role: Lecturer.
Cellular and Molecular Biology of Photoreceptors in Health and Disease. Department of Neuroscience and Ophthalmology Course. Johns Hopkins School of Medicine. 2008 Role: Lecturer.
Clinical instruction. (service, dates, role) Vitreoretinal and Ocular Oncology Service, Department of Ophthalmology, UC Davis, 1993-
2001. Role: Supervise and teach Medical Students, Ophthalmology and Family Medicine Residents, Vitreoretinal Fellows in clinic, operating room, and formal lecture series.
Retina Division, Department of Ophthalmology, Wilmer Eye Institute, 2001-present. Role: Supervise and teach Medical Students, Ophthalmology Residents, Vitreoretinal Fellows in clinic, operating room, and formal lecture series.
JT Handa, M.D. 15
15
Retina Division Surgical Teaching Conference, Wilmer Eye Institute, 2005-present. Role: Course Director of the conference which meets every other week.
CME instruction (Course title, dates, role) UC Davis "Practical Ophthalmology". April, 1993. Role: gave lecture entitled “Ocular
Manifestations of AIDS”. UC Davis "Practical Ophthalmology". September, 1993. Role: gave lecture entitled “Ocular
Manifestations of AIDS”. UC Davis Annual Symposium. May 1994. Role: gave lectures entitled 1.) Early Laser
Photocoagulation for Zone 1 ROP; 2.) The effect of Pentoxiphylline on the Progression of Diabetic Retinopathy; 3.) Detection of malignant melanoma cells from uveal melanoma in peripheral blood using polymerase chain reaction.
UC Davis Annual Symposium. May 1995. Role: gave lecture entitled “Common Retinal Problems Confronting the Comprehensive Ophthalmologist”.
UC Davis “Practical Ophthalmology for the Primary Care Physician”. May 1995. Role: gave lecture entitled AIDS and the Eye.
Vail Vitrectomy Meeting. February 1996. Role: gave lecture entitled “Laser photocoagulation of Zone 1 Retinopathy of Prematurity.”
Nantucket Retina Society Meeting. July 1996. Role: gave lecture entitled “Treatment of Subfoveal CNVM with Prednisone and Laser.”
12th Annual Meredith Morgan Symposium. Berkeley School of Optometry, Berkeley, CA. 1997. Role: gave lecture entitled “Surgical Management of Retinal Breaks and Retinal Detachment.”
UC Davis Annual Ophthalmology Symposium. 1998. Role: gave lecture entitled “Management of Intraoperative Complications during Cataract Surgery: A Vitreoretinal Surgeon’s Perspective.”
14th Annual Clinical Concepts Symposium. Wilmer Ophthalmological Institute. 2001. Role: gave lecture entitled “New approaches to determining the cause of age-related macular degeneration”.
Age-related Macular Degeneration in 2002: From Prevention to Treatment. Wilmer Ophthalmological Institute. 2002. Role: gave lecture entitled “New insights into the causes of early age-related macular degeneration”.
Wilmer Retinal Vascular Disease Symposium. Wilmer Eye Institute. 2002. New Techniques in Vitreous Surgery in the Management of Retinal Vascular Disease
The Johns Hopkins Center for Clinical Trials. Monitoring Treatment Effectiveness and Safety in Clinical Trials. 2003. role: gave lecture entitled “Collaborative Ocular Melanoma Study. Clinician’s Perspective.”
Age-related Macular Degeneration in 2004: From Prevention to Treatment and Bench to Bedside. Wilmer Eye Institute. 2004. Current Models of Non-neovascular AMD in the Laboratory Setting.
Update on Intraocular Tumors. 2005. 35th Annual Retina Division Conference. Glacier National Park, Montana.
American Academy of Ophthalmology Editor’s Choices. Discussion of 15 Year outcomes following Threshold Retinopathy of Prematurity, Final Results from the Multicenter Trial of Cryotherapy. 2005. AAO meeting, Chicago, Illinois.
Wilmer Admissions to CMSC. August 17, 2006. Department of Pediatrics Morbidity and Mortality Conference. Johns Hopkins University School of Medicine, Baltimore, MD.
Endophthalmitis. Technician Grand Rounds, Department of Ophthalmology, Johns Hopkins University School of Medicine, October 19, 2006.
Advances in Pars Plana Vitrectomy. 19th Annual Current Concepts in Ophthalmology, Johns Hopkins University School of Medicine, December 7, 2006.
JT Handa, M.D. 16
16
Strategies for Future Prevention in AMD from Lab Models. Macula 2007, Johns Hopkins School of Medicine, January 13, 2007.
Special Safety Considerations for Patients with Diabetes Undergoing Ocular Surgery. What’s New in Diabetic Retinopathy and Venous Occlusive Disease. Johns Hopkins School of Medicine, October 12, 2007.
36th Annual Pediatric Trends. Johns Hopkins School of Medicine. Retinoblastoma. April 7, 2008. Non-neovascular AMD: Future Treatments Resulting from New Discoveries. 21st Current
Concepts in Ophthalmology. Johns Hopkins University School of Medicine, Batlimore, MD, December 4, 2008.
Translational Studies Relevant to AMD. Age-Related Macular Degeneration in 2009: The Paradigm Continues to Evolve. Johns Hopkins School of Medicine. Baltimore, MD. June 13, 2009.
When Should Plaque Radiotherapy be the First Line Treatment for Choroidal Melanomas? Macula 2010. Johns Hopkins School of Medicine. Baltimore, MD, Jan 2010.
Mentoring (pre- and post-doctoral): Advisees (provide: name, dates, degree, present position, awards/grants/degrees received
under your direction.) Pre-doctoral Advisees 1. Carlton Yuen, 1998-99, UCD Medical student, 5th pathway research year. Degree: MD in
5/01. Present position: 4th year medical student. Awards: 1998 Morton Levitt Award. 2. Benhom Farboud, 1998-1999, UCD Graduate Research Assistant, level 2. Degree:
none. Present position: PhD student, UC Davis, Department of Microbiology. Awards: none.
3. Sarah Sunshine, 2010-2011. Johns Hopkins Medical Student. Recipient of Howard Hughes Medical Institute Research Training Fellowships for Medical Students.
Post-doctoral advisees 1. Harsha Sen, M.D., 1992-93, Vitreoretinal fellow, present position: Assistant Professor,
Department of Ophthalmology, Vitreoretinal Service, University of Kentucky, Lexington, KY. Awards: none.
2. Dean Eliott, M.D., 1992-93, Vitreoretinal fellow, present position: Assistant Professor, Department of Ophthalmology, Vitreoretinal Service, Henry Ford Hospital, Detroit, MI. Awards: none.
3. Alexander Eaton, M.D., 1992-93, Vitreoretinal fellow, present position: private practice (Vitreoretinal Diseases), Fort Myers, FL. Awards: none.
4. Henry Burnett, M.D., 1993-94, Vitreoretinal fellow, present position: private practice (Vitreoretinal Diseases), Winston Salem, NC. Awards: none.
5. Craig Fern, M.D., 1993-95, Vitreoretinal fellow, present position: private practice (Vitreoretinal Diseases), Westchester and New York City, NY. Awards: none.
6. Mari Ann Keithahn, M.D., 1995-96, Vitreoretinal fellow, present position: private practice (Vitreoretinal Diseases), Columbia, MO. Awards: none.
7. Andrew Chang, M.D., 1996-97, Vitreoretinal fellow, present position: Assistant Professor, Department of Ophthalmology, University of Sydney, Sydney, Australia. Awards: none.
8. Hiroshi Matsunaga, M.D., Ph.D., 1997-99, Research fellow, present position: Assistant Professor, Department of Ophthalmology, Kansai University, Osaka, Japan. Awards: none.
9. Brian Reed, M.D., 1997-98, Vitreoretinal fellow, present position: Vitreoretinal Surgeon, Brooke Army Medical Center, Fort Sam Houston, TX. Awards: none.
JT Handa, M.D. 17
17
10. Kazuaki Mishima, M.D.,1997-99, Research fellow, present position: Assistant Professor, Department of Ophthalmology, Hiroshima National University, Hiroshima, Japan. Awards: none.
11. Mitsumasa Wada, M.D., 1998-2000, Research fellow, present position Assistant Professor, Kansai University, Osaka, Japan. Awards: none.
12. James Palmer, M.D., 1998, Oncology fellow, present position: private practice, San Francisco, CA. Awards: none.
13. Adiel Barak, M.D., 1999-00, Vitreoretinal fellow, present position: Assistant Professor, Department of Ophthalmology, Tel Aviv University, Tel Aviv, Israel. Awards: none.
14. Shigeru Honda, M.D., Ph.D., 1998-2000, Research fellow, Assistant Professor, Department of Ophthalmology, Kobe University, Kobe, Japan.
15. Noritake Miyamura, M.D., 1999-2001, Research fellow, will be Assistant Professor, Department of Ophthalmology, Hiroshima National University, Hiroshima, Japan. Awards: none.
16. John Canzano, M.D., 1999, Ophthalmology resident. Degree: Residency. Present position: Vitreoretinal Fellow, University of Southern California. Award: UCD Resident Research Award.
17. Lin Chen, M.D., Ph.D., 2000, Ophthalmology resident. Present Position: 3rd year resident. Award: ARVO Travel Award for project: Distribution of collagen IV isoforms in the human posterior fundus.
18. Denise Kayser, M.D., 2000, Ophthalmology resident. Present position: 3rd year resident. Award: UCD Resident Research Award. Now a Vitreoretinal fellow at University of Iowa.
19. Byron Ladd, M.D., 2001, Vitreoretinal fellow, present position: Private practice 20. Eugene Ng, M.D., 2001, Vitreoretinal fellow, present position: Harvard Business School 21. Sharon Solomon, M.D., 2001, Vitreoretinal fellow, present position: Asst Professor,
Wilmer Eye Institute 22. Edward Quinlan, M.D., 2001, Vitreoretinal fellow, present position: Asst Professor,
Wilmer Eye Institute 23. Nine Yepez, M.D., 2001, Vitreoretinal fellow, present position: private practice 24. David DiLoreto, MD, PhD, 2002-2003, Vitreoretinal fellow, present position: Assistant
Professor, University of Rochester, Rochester, NY 25. Rajendra Apte, MD, PhD, 2002-2003, Vitreoretinal fellow, present position: Assistant
Professor, Washington University, St. Louis, MO 26. Neal Adams, MD, 2002-2003, Vitreoretinal fellow, present position: Assistant Professor,
Wilmer Eye Institute 27. Itay Chowers, MD, 2002-2003, Vitreoretinal fellow, present position: Assistant Professor,
Hadassah University, Department of Ophthalmology, Jerusalem, Israel 28. Eyal Margolit, MD, PhD, 2002-2003, Vitreoretinal fellow, present position: Assistant
Professor, University of Nebraska, Department of Ophthalmology, Lincoln, Nebraska 29. Kazuki Ishibashi, MD, PhD, 2002-2004, Post-doctoral research fellow. Position:
Assistant Professor, Kobe University, Department of Ophthalmology, Kobe, Japan 30. Justin Brown, MD, 2003-2005, Vitreoretinal fellow, present position: Private Practice,
Professor, Bascom Palmer Eye Institute, University Of Miami, Miami, FL 32. Diana Do, MD, 2003 - 2005, Vitreoretinal fellow, present position: Assistant Professor,
Wilmer Eye Institute 33. Kazuko Ishibashi, MD, 2003-2004, Post-doctoral research fellow. Position: Assistant
Professor, Kobe University, Department of Ophthalmology, Kobe, Japan. 34. Eric Tourville, MD, 2004 - 2006, Vitreoretinal fellow. Present position: Asst Professor,
Centre Hospitalier Universite Laval, Quebec, Canada
36. Brian Kim, MD, 2004-2006, Vitreoretinal Fellow, Present Position: Private Practice, Burlington, VT
37. Yuko Yamada, MD, 2004-2006, Post-doctoral research fellow. Position: Assistant Professor, Kobe University, Department of Ophthalmology, Kobe, Japan
38. Joanna Oda, MD. 2005 - 2007, Vitreoretinal fellow, Present Position: Private Practice, New York City, NY
Wilmer Eye Institute. 50. Benjamin Kim, MD, 2008-2010, Vitreoretinal fellow. Present position: Private practice,
Florida 51. Bryan Propes, MD, 2008-2010. Vitreoretinal fellow. Present position. US Navy, San
Diego, CA. 52. Marisol Cano, PhD. 2008-2010. Post-doctoral research fellow. Present position:
Research Associate, Wilmer Eye Institute. 53. Naoshi Kondo, MD, PhD. 2009-2011, Post-doctoral research fellow. Present position:
Assistant Professor, Kobe University, Kobe, Japan 54. Katayoon Ebrahimi, MD. 2009-. Post-doctoral research fellow. 55. Thomas Lee, MD. 2009-2011. Vitreoretinal Fellow. 56. Shiri Zayit-Soudry, MD. 2009-2011. Vitreoretinal Fellow. 57. Muge Kesen, MD. 2009-2011. Vitreoretinal Fellow. 58. Adam Wenick, MD, PhD. 2010-2012. Vitreoretinal Fellow. 59. Ala Moshiri, MD, PhD. Vitreoretinal Fellow. 60. Alex Leder, MD. Vitreoretinal Fellow. 61. Lei Wang, PhD. 2009-. Post-doctoral research fellow. 62. Keiichi Mitarai, M.D.. 2011-. Post-doctoral research fellow. 63. Mizumi Tagami, M.D., Ph.D. 2011-. Post-doctoral research fellow. Thesis committees:
1. VK Gullipalli. Institute of Ophthalmology and Visual Science, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Newark, New Jersey, USA. 2005
JT Handa, M.D. 19
19
2. Jae Ho Han. Department of Electrical and Computer Engineering, Johns Hopkins University, Baltimore, MD. Chairman, Graduate Board Oral Examination. 2008
3. Anton Kollomeyer. Institute of Ophthalmology and Visual Science, University of Medicine and Dentistry of New Jersey-New Jersey Medical School, Newark, New Jersey, USA. 2010
4. Karen Weikel. Tufts University, Boston, MA. Training grant participation: none Editorial Activities: Editorial Board appointments Investigative Ophthalmology and Visual Science Vision and Aging Guest Editor, Current Eye Research Journal peer review activities: Peer reviewer for Acta Ophthalmologica Scandinavica, Am J
Ophthalmol, Arch Ophthalmol, Biochimica et Biophysica Acta, British J Ophthalmol, Cornea, Current Eye Research, Diabetes, Diabetes and its Complications, Exp Cell Res, Exp Eye Res, Invest Ophthalmol Vis Sci, Retina, Ophthalmology, Molecular Biology of the Cell, Proc Natl Acad Sci., Physiological Genomics, Survey of Ophthalmology, Science Translational Medicine.
Book reviewer; Am J Ophthalmol, Ophthalmic Surg CLINICAL ACTIVITIES: Certification: UPIN#: E23229 Tax ID#: 520595110 Medical, other state/government licensure (date, identification #) DEA Registration Certificate: 10/08/98-present. Identification #: BH2276877. Maryland, 2001-present. Identification #: D0057248 Maryland Controlled Substances license. Identification #: M48939 California, 1991 - present. Identification #: G 072097. Nevada, 1994 - 95. Identification #: 7223. North Carolina, 1990 - 94. Identification #: 38967. Pennsylvania,1987 - 90. Identification #: MD-040837-E. Boards, other specialty certification (date, identification #): National Board of Medical Examiners Certification: July 1, 1987. Certificate # 319571. American Board of Ophthalmology, 1991. Diplomate. American Board of Ophthalmology, 1992. Fellow, Member # 059614 Service Responsibilities (specialty-role, time commitment): Specialty: Vitreoretinal Diseases and Intraocular Oncology. Role: Medical and surgical
treatment of vitreoretinal diseases and intraocular oncology, Time commitment: 40%. ORGANIZATIONAL ACTIVITIES Institutional Administrative Appointments (committees, dates): Admissions Committee interviewer, School of Medicine (UCD), 1995-2001. Ad Hoc Appointment and Promotion Committee (UCD), observer, 1997. Faculty Advisor for Medical Students (UCD), 1998-2001.
JT Handa, M.D. 20
20
Member, Research Committee, Wilmer Eye Institute Member, CPAC, Wilmer Eye Institute, 2002-present Member, Medical Student Education Committee, Wilmer Eye Institute, 2002-present. Member, ORMS Physician Committee, Johns Hopkins Medical Institutes, 2002-present. Member, Blue Ribbon Panel, Wilmer Eye Institute, 2003-present. Investigates
Operating room efficiency. Member, Space Allocation Committee, 2004. Chair, Committee on Evaluation of K-grant Progress, 2004-present. Member, Neuro-Ophthalmology Search Committee, 2005-2006. Associate Division Chief, Retina Service, Wilmer Eye Institute, 2005-present. Vice Chair, Department of Ophthalmology, Quality Assurance and Quality Improvement,
Wilmer Eye Institute, 2006-present Member, Clinical Quality Improvement Committee, The Johns Hopkins Hospital, 2006-
present Member, “Wilmer 2010” Steering Committee and Implementation Team, 2006-present Member, “Wilmer Digital Steering Committee”, 2007-present. Member, Pediatric Opthalmology Search Committee, 2007-present Member, Retina Search Committee, 2007-present. Chair, Wilmer Strategic Research Planning Committee, 2008-2009. Member, Advisory Committee to Vice-Chair of Research, 2010-present. Professional Societies (membership, committees, dates, role):
Association for Research in Vision and Ophthalmology, 1985-present. Role: member; Member #33085
American Medical Association-1986-present. Role: member. American Academy of Ophthalmology- 1988-present. Role: member. Alta California Ophthalmologic Society-1993-present. Role: member. California Ophthalmologic Society-1999-present. Role: member. International Congress of Eye Research-2000-present. Role: member. Retina Society-2002-present. Role: member. Macula Society-2002-present. Role: member. Conference Organizer, Session Chair (sponsor, date, role): International Congress on Ocular Neovascularization, Kyoto Japan. 1997. Role: Chair of
session on Age-related Macular Degeneration. Special Interest Group (SIG). Update on age-related macular degeneration. Chairman.
ARVO, Ft. Lauderdale, FL. 2002. Special Interest Group (SIG). Update on age-related macular degeneration. Chairman.
ARVO, Ft. Lauderdale, FL. 2003. Special Interest Group (SIG). Cholesterol and lipoproteins in retinal health and Age-
related maculopathy. ARVO, Ft. Lauderdale, FL 2009. Special Interest Group (SIG). Cholesterol and lipoproteins in retinal health and Age-
related maculopathy. ARVO, Ft. Lauderdale, FL 2010. Special Interest Group (SIG). Cholesterol and lipoproteins in retinal health and Age-
related maculopathy. ARVO, Ft. Lauderdale, FL 2011. Advisory Committees, Review Groups (sponsor, date, role):
International Committee on the Classification of Intraocular Retinoblastoma, Toronto, Canada.1994. Role: member.
California Department of Corporations. Health Plan Division. 1998-present. Role: review cases involving claims against HMOs.
Special Reviewer. 1996-02. VISC Study Section, National Eye Institute. Role: reviewer for RO-1 grants.
Reviewer for Medical Research Council Grants, London, UK. 2000. Role: reviewer for MRC grants.
Reviewer for Juvenile Diabetes Research Foundation, site visit, Schepen’s Eye Institute, Boston, MA. 2002-2003. Role: reviewer for JDRF Center grant
Advisory Board Member for Center for Computer-Integrated Surgical Systems and Technology. A National Science Foundation Engineering Research Center. Johns Hopkins University. 2003. Role: provide clinical direction for imaging and robotic designs.
Reviewer for Raine Medical Research Foundation, Nedlands, Australia. 2003 Retina Expert Advisory Meeting. 2004. Dallas, TX. Role: to provide a discussion
on classification and treatment of wet age-related macular degeneration. (29 retina experts from around the world)
Ad hoc reviewer, Board of Scientific Counselors, National Eye Institute. 2005. Role: reviewed intramural researchers at the National Eye Institute.
Ad hoc reviewer, Health Research Board, Ireland. 2005. Role: reviewed extramural research proposal.
Member, American Academy of Ophthalmology Research Selection Committee (Selection of retina courses for the AAO meeting, 2007), 2006
Member, Macula Society Research Committee, 2006. Member, Alcon Retina Advisory Council (RAC), 2006-2009 NEI Study Section Cell Biology IRG, October 26, 2006. Role: Reviewer Reviewer, American Academy of Ophthalmology, Annual Meeting Program Committee -
Retina/Vitreous 2007 (for AAO meeting 2008) Reviewer, Challenge Grants RC1, NEI, 2009. Reviewer, VA Grants, March, 2010 Distinguished Reviewer, ZRG1 CB-G 90 NEI Grant Reviewer, 2010 Reviewer, Thome Foundation AMD Grants, 2011.
Consultantships (organization/agency, date, role): Elon Pharmaceuticals, South San Francisco, CA, 2000-present. Role: Advise regarding
advanced glycation endproduct (AGE) formation and anti-AGE antibody synthesis.
Lexicon Genetics, The Woodlands, TX, 2000-present. Role: Ophthalmologic advisor regarding ocular phenotyping of knockout mice.
Alcon, Inc. Fort Worth, TX, 2006-2009. Role: Vitreoretinal surgery advisor regarding novel surgical system development.
RECOGNITION Awards, honors (title, date, description, sponsor): Sigma Xi Honor Society. 1981. Brown University.
Oliver Memorial Prize in Ophthalmology. 1986. Best medical student research project. University of Pennsylvania School of Medicine.
Alpha Omega Alpha Honor Society. 1986. University of Pennsylvania School of Medicine.
Chief Resident. 1989. Wills Eye Hospital. Philadelphia, PA. ARVO Travel Fellowship. 1992. Recognition for Research project. Association for
Research in Vision and Ophthalmology.
JT Handa, M.D. 22
22
James and Virginia Hornaday Award. 1992. Outstanding Fellow, Duke Eye Center. Named to “Best Doctors in America, Pacific Region”. 1995. Named to “Top Doctors in Sacramento”. 1996. Named to “Best Doctors in America”. 1998. Named to “Best Doctors in Baltimore”. Baltimore Magazine, 2002. Guide to America’s Top Ophthalmologists, 2004 Inaugural Thomas Orton Jones Fellowship in Age-related Macular Degeneration, 2005.
Named to “Best Doctors in America”, 2005-2006. Named to “America’s Top Doctors for Cancer, 2nd Edition, Castle Connolly Medical LTD, 2006 Named to “Best Doctors in America, 2007-2008 Named to “America’s Top Doctors, 7th Edition, 2007 Named to Best Doctors, Baltimore Magazine, 2007 Robert Bond Welch, MD Professor of Ophthalmology, 2008 Named to “America’s Top Doctors for Cancer”, 4th Edition, 2008 ARVO Fellow, Silver medal, 2009 AAO Achievement award, 2009 Named to “Best Doctors in America” 2009 Named to America’s Top Doctors for Cancer, 5th Edition Castle Connolly Medical LTD, 2009
Named to America’s Top Doctors for Cancer, 5th Edition Castle Connolly Medical LTD, 2010 Invited Talks, Panels (title, date, venue, sponsor): A New Classification for Retinoblastoma. 1994. International Committee on the Classification of
Intraocular Retinoblastoma, ICER meeting. Toronto, Canada. Retinoblastoma: its diagnosis and a novel treatment approach. 1994. Visiting Professor
Rounds. Department of Ophthalmology, University of Minnesota, Minneapolis, MN. Laser photocoagulation of Zone 1 Retinopathy of Prematurity. 1996. Vail Vitrectomy Meeting. Intraocular Tumors. 1996. Sacramento Valley Optometric Society Meeting, Sacramento, CA. An Unusual Eye Tumor. 1996. Pulse Segment, KXTV Channel 10, Sacramento, CA. The ocular complications of diabetic retinopathy. 1996. Belau National Hospital Grand Rounds,
Republic of Palau, Micronesia. The diagnosis and treatment of cataract. 1996. Belau National Hospital Grand Rounds,
Republic of Palau, Micronesia. Age-related Macular Degeneration. 1996. Simmons College, Boston, MA. Treatment of Subfoveal CNVM with Prednisone and Laser. 1996. Nantucket Retina Society
Meeting. Diagnosis and Treatment of Cataract. 1997. Belau National Hospital Grand Rounds, Republic
of Palau, Micronesia. Diagnosis and Treatment of Diabetic Retinopathy. 1997. Belau National Hospital Grand
Rounds, Republic of Palau, Micronesia. Surgical Management of Retinal Breaks and Retinal Detachment. 12th Annual Meredith Morgan
Symposium. 1997. Berkeley School of Optometry, Berkeley, CA. Pentosidine induces PDGF-B chain expression in ARPE-19 RPE cells. 1997. 5th International
Symposium on Ocular Circulation and Neovascularization. Kyoto, Japan. The role of nonenzymatic glycation and senescence in aging. 1997. Visiting Professor Rounds,
Kyoto University, Kyoto, Japan. Guide to interpretation of fluorescein angiography. 1998. Invited speaker. Berkeley School of
Optometry, Berkeley, CA.
JT Handa, M.D. 23
23
Management of Diabetic Retinopathy. 1998. Belau National Hospital. Visiting Professor Rounds, Republic of Palau, Micronesia.
Diagnosis and Treatment of the Red Eye. 1998. Belau National Hospital. Visiting Professor Rounds, Republic of Palau, Micronesia.
New Directions in Macular Degeneration Research. 1998. Macular Degeneration Society. Sacramento, CA.
Diagnosis of Diabetic Retinopathy for the Primary Care Doctor. Belau National Hospital. 1999. Visiting Professor Rounds, Republic of Palau, Micronesia.
Care of the Age-related Cataract in Palau. 1999. Belau National Hospital. Visiting Professor Rounds, Republic of Palau, Micronesia.
New Approaches in the Treatment of Retinoblastoma. 1999. 40th Annual Conference of the California Transcribers and Educators of the Visually Handicapped. Sacramento, CA.
Intraoperative and Postoperative Management of the Pediatric Retinal Surgery Patient. 20th Annual California Perianesthesia Nurses Meeting. 1999. Pleasanton, CA.
Giving back to the Community. Palau. A Tropical Island Fighting Diabetic Eye Disease. 1999. 6th Annual Asian Pacific American Medical Student Association National Conference. San Francisco, CA.
Distribution of collagen IV isoforms in the posterior fundus. 2000. Vail Vitrectomy meeting. Diagnosis and Management of the Red Eye. 2000. Belau National Hospital. Visiting Professor
Rounds, Republic of Palau, Micronesia. The pathogenesis of diabetic retinopathy and age-related macular degeneration as it relates to
CTGF expression and fibrosis. 2000. Fibrogen, Inc. South San Francisco, CA. New theories to the pathogenesis of age-related macular degeneration. 2000. Invited Speaker,
Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore,MD Do AGEs induce aging of the RPE? 2000. Invited speaker to Neurosciences Lecture Series,
Johns Hopkins School of Medicine, Baltimore, MD. Microarray Analysis of an mRNA phenotype induced by AGE-matrix. 2000. Invited Speaker,
International Congress of Eye Research meeting, Santa Fe, NM The role of advanced glycation endproducts in diabetic retinopathy and age-related macular
degeneration. 2000. Elon Pharmaceuticals, South San Francisco, CA. The use of laser capture microdissection and microarray analysis to determine an mRNA
phenotype of the retinal pigment epithelium in Age-related macular degeneration. 2001. Lexicon Genetics, The Woodlands, TX.
Novel approaches to the cause of Age-related macular degeneration. 2001. Wilmer Advisory Council. Baltimore, MD.
Gene expression profiles of human RPE in vitro and in vivo by microarray analysis. 2001. Western Eye Regional Conference, Lake Tahoe, CA.
New insight into the pathogenesis of age-related macular degeneration. 2001. 14th Annual Wilmer Current Concepts Meeting, Baltimore, MD.
Determining an aging mRNA phenotype of the retinal pigment epithelium by microarray analysis. 2002. National Institute of Dentistry and Craniofacial Research, Bethesda, MD.
The transition of the RPE from aging to Age- related macular degeneration. 2003. Visiting Professor. University of Iowa, Iowa City, IA.
Understanding the transition from aging to Age-related macular degeneration. 2003. Visiting Professor. University of Pennsylvania, Philadelphia, PA
The future of fine needle biopsy to guide the treatment of choroidal melanoma. 2003. Visiting Professor. University of Pennsylvania, Philadelphia, PA
The role of advanced glycation endproducts in RPE aging. 2004. Visiting Professor. University of Medicine and Dentistry of New Jersey, Newark, NJ
AMD. Many Treatments, but what are the options? 2004. Visiting Professor. University of South Florida. Tampa, FL
JT Handa, M.D. 24
24
Management of Posterior Capsular Rupture: The Retinal Surgeon’s Perspective. 2004. Visiting Professor. University of South Florida. Tampa FL.
Case Presentations of Retina Problems. 2004. Visiting Professor. University of South Florida. Tampa, FL
Update on Management of Uveal Melanoma. 2005. 35th Anniversary, Retina Division Wilmer Eye Institute, Glacier National Park, Montana
New insights into AMD. Maryland Ophthalmological Society, 2005. Baltimore, MD. AGEs and Aging Bruch’s Membrane. Tackling Early AMD: Devising New Strategies to Prevent
Visual Loss. 2005. Sonoma, California. The impact of AGEs in Bruch’s membrane with aging and early AMD. 2005. National Eye
Institute, NIH, Bethesda, MD. Managing Retinal Manifestations in the Marfan Syndrome. July 6, 2006. National Marfan
Foundation Ophthalmologic Research and Clinical Management Workshop, Philadelphia, PA.
Diagnosis and Management of Ocular Melanoma. October 13, 2006. Grand Rounds, Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD
Aging of the Retinal Pigment Epithelium. May 18, 2007. 24th Annual Wilmer Nursing Conference, Johns Hopkins University, Baltimore, MD
What Triggers the Onset of Age-related Macular Degeneration? October 18, 2007. Jeffrey Berger Memorial Lecture, Scheie Eye Institute, Philadelphia, PA
Oxidized Lipoproteins in the Bruch Membrane Induce Pathologic Changes in the RPE in AMD. April 24, 2008. 16th Advanced Vitreous Surgery Course, Duke University School of Medicine, Durham, NC
Do Statins Locally Inhibit Lipoprotein Secretion by the RPE? April 24, 2008. 16th Advanced Vitreous Surgery Course, Duke University School of Medicine, Durham, NC
Integrating Preoperative Images on the Surgeon’s Intraoperative View. April 25, 2008. 16th Advanced Vitreous Surgery Course, Duke University School of Medicine, Durham, NC
Overview of an Integrated New Vitreoretinal Surgical System. April 25, 2008. 16th Advanced Vitreous Surgery Course, Duke University School of Medicine, Durham, NC
A simplified approach to categorizing non-neovascular AMD. Keynote Speaker, University of California-Davis Ophthalmology Symposium; Napa Valley, CA, May 16-18, 2008
How Genetics has Changed the Paradigm of AMD. Keynote Speaker, University of California-Davis Ophthalmology Symposium; Napa Valley, CA, May 16-18, 2008
Current and Future treatments for non-neovascular AMD. Keynote Speaker, University of California-Davis Ophthalmology Symposium; Napa Valley, CA, May 16-18, 2008
An Integrated Microsurgical Platform for Enhanced Surgical Performance, Alumni Day Grand Rounds, Duke University Eye Center, Durham, NC. October 24, 2008.
An Integrated Microsurgical System. I4M Lecture Series, Johns Hopkins School of Medicine. November 19, 2008.
Barriers to improved microsurgical performance. Featured speaker, School on Medical Robotics and Computer-integrated Interventional Medicine Winter School Course, Johns Hopkins Univerisity, Baltimore, MD. January 13, 2009
A smoke induced animal model of AMD. Twelfth Annual Vision Research Conference - Mechanisms of Macular Degeneration. Pre-ARVO Meeting, 2009. Ft Lauderdale, FL. May 2009
Translational Studies Relevant to AMD. Age-Related Macular Degeneration in 2009: The Paradigm Continues to Evolve. Johns Hopkins School of Medicine. Baltimore, MD. June 13, 2009.
Making Smart Microsurgical Instruments. Inspiration from Robert Machemer. Robert Machemer, MD. Progress Comes from Doing the Unconventional. Tribute to Robert Machemer, May, 2010
JT Handa, M.D. 25
25
How Does the Retinal Pigmented Epithelium Respond to Cigarette Smoke? ISER July, 2010, Montreal, Canada.
Heed Foundation Meeting for Residents. Chicago, Ill, October 2010 Smart Microsurgical Instruments for Vitreoretinal Surgery. Wills Eye Institute 50th anniversary
meeting, Philadelphia, PA. January 30, 2011. Evidence for Smoking and Lipoproteins in AMD. David Rich Lecture. University of Alabama,
Birmingham, Birmingham, Ala. March 23, 2011. Treating Non-neovascular AMD. Resident Lecture. University of Alabama, Birmingham,
Birmingham, Ala. March 23, 2011. OTHER PROFESSIONAL ACCOMPLISHMENTS Goodwill Ophthalmology Mission, Republic of Palau, Micronesia, 1994-present. Management of
diabetic retinopathy, cataracts, pterygium, and other ophthalmologic diseases. Contracted by the Republic of Palau, Ministry of Health.
